{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0"},{"groupId":"OG001","value":"92.2"},{"groupId":"OG002","value":"92.8"},{"groupId":"OG003","value":"87.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"},{"groupId":"OG001","value":"7071"},{"groupId":"OG002","value":"305"},{"groupId":"OG003","value":"7078"}],"units":"Participants"}],"description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. An AE that is judged by the investigator to be \"definitely related,\" \"probably related,\" or \"possibly related\" to the study drug is defined as a vaccine-related AE.","groups":[{"description":"V503 (9-Valent HPV Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study.","id":"OG000","title":"Low-dose V503"},{"description":"V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.","id":"OG001","title":"Mid-dose V503"},{"description":"V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study.","id":"OG002","title":"High-dose V503"},{"description":"Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study. Participants (Cohort 2) were offered the V503 mid-dose 3-dose regimen in the extension study.","id":"OG003","title":"Gardasil"}],"paramType":"NUMBER","populationDescription":"The analysis population included all participants who received \\>=1 vaccination and had safety follow-up","reportingStatus":"POSTED","timeFrame":"Up to Month 7 (low- and high-dose V503) or up to Month 54 (mid-dose V503 and Gardasil)","title":"Base Study: Percentage of Participants With One or More Vaccine-related Adverse Event","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}